TABLE 4.
Baseline nonselective beta‐blocker concentration and time to first fall.
N | Model 1 c HR (95%CI) | p‐value | N | Model 2 d HR (95%CI) | p‐value | |
---|---|---|---|---|---|---|
Continuous concentration | ||||||
Nonselective beta‐blocker a | 179 | 0.936 (0.76–1.15) | .523 | |||
Timolol | 70 | 1.006 (0.69–1.47) | .974 | 54 | 1.075 (0.71–1.62) | .729 |
Sotalol | 73 | 1.000 (0.99–1.00) | .948 | |||
Concentration divided on median b | ||||||
Nonselective beta‐blocker a | 179 | 0.953 (0.65–1.40) | .809 | |||
Timolol | 70 | 1.131 (0.61–2.08) | .692 | 54 | 1.247 (0.63–2.48) | .530 |
Sotalol | 73 | 1.042 (0.56–1.95) | .896 | |||
Concentrations are divided into four quartiles | ||||||
Nonselective beta‐blocker a | 179 | 138 | ||||
First quartile | Ref. | Ref. | ||||
Second quartile | 1.020 (0.60–1.73) | .941 | 1.183 (0.64–2.19) | .593 | ||
Third quartile | 1.319 (0.80–2.17) | .278 | 1.413 (0.80–2.49) | .233 | ||
Fourth quartile | 0.725 (0.41–1.29) | .275 | 0.779 (0.40–1.50) | .455 | ||
Timolol | 70 | |||||
First quartile | Ref. | |||||
Second quartile | 0.904 (0.37–2.23) | .827 | ||||
Third quartile | 1.616 (0.69–3.80) | .271 | ||||
Fourth quartile | 0.996 (0.38–2.62) | .994 | ||||
Sotalol | 73 | |||||
First quartile | Ref. | |||||
Second quartile | 1.398 (0.45–4.31) | .560 | ||||
Third quartile | 1.384 (0.45–4.22) | .568 | ||||
Fourth quartile | 0.793 (0.24–2.58) | .700 |
Note: Data presented as hazard ratio with a 95% confidence interval. Nonselective beta‐blockers: timolol, sotalol, propranolol, carvedilol.
Abbreviations: N, number of analyzed plasma concentrations; CI, confidence interval.
Number of events model: nonselective beta‐blockers = 104; timolol = 43; sotalol = 44. Number of events model 2: timolol = 35; nonselective beta‐blockers = 85. A systemic timolol concentration was measured in 45% of our timolol users.
Median timolol: 0.0145 ng/mL. Median sotalol: 704.00 ng/mL.
Model 1 was adjusted for age and gender.
Model 2 was adjusted for age, gender, and: timolol continue and median: cardiovascular (CV) disease; nonselective beta‐blockers quartiles: CV disease. No model 2 was constructed for nonselective beta‐blockers and sotalol continuous and median concentrations or for timolol and sotalol quartiles because either none of the variables changed the outcome more than 10%, or the number of events was too low to add covariates to the model.